Nivolumab and interferon-γ rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Medical Mycology Case Reports Year : 2022

Nivolumab and interferon-γ rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock

Abstract

Immunosuppression is a major feature of septic shock and patients are at increased risk for opportunistic infections. We describe a successful use of immunostimulation to treat mixed mould and bacterial superinfection in a previously healthy 38-year-old female patient admitted for severe extensive fasciitis. Interferon gamma associated with nivolumab reversed successfully deactivation of immune cells assessed by altered expressions of monocyte human leukocyte antigen-DR (HLA-DR) and lymphocyte programmed death receptor-1 (PD-1). Immunosuppressed patients in ICU with invasive bacterial and fungal infections may benefit from immunostimulation.
Fichier principal
Vignette du fichier
1-s2.0-S2211753922000252-main.pdf (2.36 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-04010258 , version 1 (01-03-2023)

Identifiers

Cite

Anne-Claire Lukaszewicz, Fabienne Venet, André Boibieux, Mathilde Lherm, Bertrand Devigne, et al.. Nivolumab and interferon-γ rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock. Medical Mycology Case Reports, 2022, 37, pp.19-22. ⟨10.1016/j.mmcr.2022.06.003⟩. ⟨inserm-04010258⟩
6 View
37 Download

Altmetric

Share

Gmail Facebook X LinkedIn More